Canada markets open in 7 hours 40 minutes

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
1.4900-0.1100 (-6.88%)
At close: 3:46PM EDT
Full screen
Previous Close1.6000
Open1.6100
Bid1.4700 x 0
Ask1.5000 x 0
Day's Range1.4700 - 1.6400
52 Week Range1.2100 - 2.9600
Volume63,835
Avg. Volume28,155
Market Cap56.269M
Beta (5Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-0.3480
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291

    Remains on Track to Dose First Subjects in Q2 2021 Vancouver, British Columbia--(Newsfile Corp. - April 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, has received approval and guidance from the Bellberry Human Research Ethics Committee ("HREC") in Australia on the design of a Phase 1 clinical trial for NVG-291, a specific ...

  • Newsfile

    NervGen Pharma Reports 2020 Year End Results

    Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.Paul Brennan, NervGen's President & CEO, stated, "We made substantial progress in the development of our lead program, NVG-291, towards clinical trials during 2020. We were ...

  • Newsfile

    NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury

    Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the European Medicines Agency ("EMA") has granted Orphan Designation for the treatment of spinal cord injury ("SCI") to NVG-291, a specific and selective protein tyrosine phosphatase sigma ("PTPσ") inhibitor. This new EMA designation provides NervGen ...